Gilead Sciences has secured the approval of the US Food and Drug Administration (FDA) for Trodelvy (sacituzumab govitecan-hziy) for pre-treated HR+/HER2- metastatic breast cancer. The Trop-2 directed antibody-drug conjugate (ADC) is indicated for the treatment of adults having unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer […]
Sunlenca FDA approval : Gilead Sciences has secured the approval of the US Food and Drug Administration (FDA) for Sunlenca (lenacapavir), in combination with other antiretroviral(s), for the treatment of human immunodeficiency virus type 1 (HIV-1). Sunlenca, a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, in combination with other antiretroviral(s), is indicated for the […]
Gilead Sciences has secured expedited approval from the US Food and Drug Administration (FDA) for its nucleotide analog Veklury (remdesivir) for the treatment of non-hospitalized patients at high risk for Covid-19 disease progression. The Covid-19 drug has been indicated for adults and adolescents. Veklury has been the antiviral standard of care for the treatment of […]
Gilead Sciences acquisition of MYR : US biopharma giant Gilead Sciences has agreed to acquire MYR, a German biotech company engaged in developing therapies for chronic hepatitis delta virus (HDV), in a deal worth up to €1.45 billion. The consideration consists of nearly €1.15 billion in cash, which will be paid at the time of […]
Gilead Sciences has wrapped up its previously announced $21 billion acquisition of New Jersey-based biopharma company Immunomedics. With the completion of the deal, Immunomedics has now become a fully-owned subsidiary of Gilead Sciences. The common stock of Immunomedics will be delisted from the Nasdaq Global Market. Immunomedics, which has been acquired for $88 per share […]
Remdesivir FDA approval : Gilead Sciences, a California-based biopharma company, has bagged approval from the US Food and Drug Administration (FDA) for its antiviral drug Veklury (remdesivir) for Covid-19 treatment in patients requiring hospitalization. This makes remdesivir the first approved treatment for coronavirus in the US. Remdesivir FDA approved indication : Veklury has been approved […]
Jyseleca EC approval : Gilead Sciences and Galapagos have secured marketing authorization for Jyseleca (filgotinib 200 mg and 100 mg tablets) from the European Commission (EC) for the treatment of moderate to severe active rheumatoid arthritis (RA) in adults. The approval of the once-daily, oral, JAK1 inhibitor is rheumatoid arthritis patients who showed inadequate response […]
Gilead acquisition of Immunomedics : US pharma giant Gilead Sciences has signed a $21 billion worth deal to acquire New Jersey-based biopharma company Immunomedics to gain access to the latter’s FDA approved breast cancer drug Trodelvy (sacituzumab govitecan-hziy). Immunomedics, which has been offered $88 per share in cash by the US pharma giant, is focused […]
Gilead Sciences has agreed to acquire a stake of 49.9% in California-based cancer immunotherapy company Pionyr Immunotherapeutics, for $275 million. The pharma major has also secured an exclusive option to acquire the remaining stake in Pionyr Immunotherapeutics. As per the agreement, shareholders of the cancer immunotherapy company could be paid an additional $1.47 billion in […]
Remdesivir EUA status : The US has officially pushed the use of remdesivir for treating the novel coronavirus with the Food and Drug Administration (FDA) granting emergency use authorization (EUA) to the investigational COVID-19 drug candidate being developed by Gilead Sciences. The EUA lets the antiviral drug candidate to be used for the treatment of […]
